 BCMACD19 dual-targeting FasTCAR-T GC012F demonstrated 100 ORR and 100 MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Nov. 3, 2022 PRNewswire -- Gracell Biotechnologies Inc. Gracell or the Company, NASDAQ: GRCL, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the first clinical data of its ongoing Phase 1, investigator-initiated study in China evaluating FasTCAR-enabled GC012F in newly diagnosed, transplant-eligible, high-risk multiple myeloma NDMM patients. 